Refer label for a detailed indication. Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg have an estimated market size of US$ 28.2 million for twelve months ending ...

Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem ...

Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic ...

Alembic Pharmaceuticals Ltd has secured final approval from the USFDA for its generic Diltiazem Hydrochloride ...

Alembic has a cumulative total of 218 ANDA approvals (191 final approvals and 27 tentative approvals) from USFDA, it added.

Alembic Pharmaceuticals receives USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules, indicated ...

Alembic Pharmaceuticals Limited announced today it has received final approval from the US Food & Drug Administration (USFDA) ...

Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg. According to the company’s statement, the approved ANDA is therapeutically equivalent to the reference listed ...

Alembic Pharmaceuticals received final USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules, designed to treat hypertension. Available in multiple strengths, these capsules ...

These capsules will be available in dosages of 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, offering a generic alternative to ...

Mumbai: Drug maker Alembic Pharmaceuticals Ltd has recently announced that it has received final approval from the United States Food and Drug Administration (USFDA) for the abbreviated new drug ...

Alembic Pharmaceuticals stated that it gained final FDA approval for the Diltiazem Hydrochloride Extended-Release capsules, ...